With more than 35 years of experience in the pharmaceutical industry, Sylvie Ducharme is recognized as one of Canada’s leading experts in regulatory affairs and drug development. She began her career in pharmacokinetics and nonclinical research at ClinTrials Bioresearch (now Charles River Laboratories) before advancing into senior regulatory roles at Aventis Pharma (Sanofi), Lundbeck Canada, Paladin Labs, Knight Therapeutics, and now Devonian Health Group.
Throughout her career, Sylvie has led the preparation of over 50 regulatory dossiers submitted to Health Canada, including 32 New Drug Submissions—achieving an exceptional approval record. Her regulatory expertise spans synthetic drugs, biologics, medical devices, and natural health products across a wide range of therapeutic areas.
A certified Regulatory Affairs professional (RAC), Sylvie is also a dedicated educator. Since 2001, she has served as a faculty member in the Université de Montréal’s graduate Drug Development program, where she teaches Canadian and international regulatory frameworks.
Fluent in French and English, Sylvie combines scientific rigor, regulatory insight, and a passion for mentorship—shaping the future of pharmaceutical innovation in Canada.